metadata toggle
Clinical particulars
Target species
Indications for use
For active immunisation of dogs to reduce infection with Leptospira interrogans serogroup canicola and Leptospira interrogans serogroup icterohaemorrhagiae.
Specific claims:
The duration of immunity induced by the vaccine was established as at least one year.
Nobivac Lepto 2 significantly reduces the number of animals which develop a urinary tract infection which can predispose to development of a carrier condition after L. canicola and
L. icterohaemorrhagiae infection.
Only healthy dogs should be vaccinated.
Special warnings for each target species
The vaccine may not be effective in dogs incubating the disease at the time of vaccination.
Animals that have received the corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration.
Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Special precautions for use
Operator warnings: None.
Adverse reactions
A local reaction of limited size may occur during the first few days after vaccination.
After subcutaneous administration with the DHPPi, Pi, Parvo-C and/or rabies vaccines of the Nobivac series a diffuse swelling may be observed at the injection site in most puppies. Occasionally this swelling may be hard and painful but this will diminish gradually and will disappear after 2 - 3 weeks.
In the rare event of a hypersensitivity reaction following vaccination, administer an antihistamine, corticosteroid or adrenaline, without delay and by the most immediate route.
Use during pregnancy, lactation or lay
The vaccine has been shown to be safe for use in pregnant bitches which have previously been vaccinated with Nobivac Lepto 2.
Safety and/or efficacy data are available which demonstrate that this vaccine can be mixed with live vaccines from the Nobivac range containing Canine distemper virus (strain Onderstepoort), Canine adenovirus type 2 (strain Manhattan LPV3), Canine parvovirus (strain 154) and/or Canine parainfluenza virus (strain Cornell).
Safety and/or efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with the inactivated rabies (strain Pasteur RIV) vaccine for the Nobivac range.
Amounts to be administered and administration route
The contents of one vial (1 ml) should be administered by subcutaneous injection.
Allow the vaccine to reach room temperature (15 °C - 25 °C) before use. Sterile injection equipment should be used.
Primary course vaccination:
All dogs not previously vaccinated should be vaccinated twice 2 - 4 weeks apart. Puppies should be at least 6 weeks of age before they receive the first vaccination.
Booster vaccination
A single annual booster dose is recommended.
Nobivac Lepto 2 may be used to reconstitute Nobivac DHPPi, DHP, Pi or Parvo-C as indicated in the appropriate package leaflets.
For more detailed advice on vaccination programmes and how the product may be used in conjunction with other Nobivac dog vaccines in specific circumstances contact the company direct or refer to the support literature.
No particular symptoms at double dose (see section “ Adverse reactions”).
Withdrawal periods
Not applicable.